📗 Cite This Artifact
Vivoryon Therapeutics
Overview
Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for [Alzheimer's disease](/diseases/alzheimers-disease) and other neurodegenerative conditions. Headquartered in Amsterdam, Netherlands, with operations in Munich, Germany, Vivoryon is pioneering a novel approach targeting glutaminyl cyclase (QC) inhibition to prevent the formation of toxic [amyloid-beta](/proteins/amyloid-beta) oligomers[@vivoryon].
The company was founded in 2006 as a spin-off from the University of Munich (LMU), leveraging over a decade of academic research on the role of glutaminyl cyclase in neurodegenerative disease. Vivoryon's lead candidate, varoglutamstat (formerly PQ912), represents one of the few disease-modifying approaches in clinical development that targets a specific toxic amyloid-beta species rather than amyloid plaque formation broadly.
Company Profile
| Attribute | Details |
|-----------|---------|
| Headquarters | Amsterdam, Netherlands (legal) |
| Operations | Munich, Germany |
| Founded | 2006 |
| Stock Exchange | Euronext Amsterdam |
| Ticker | VVY |
| Employees | ~50 |
| Market Cap | ~€50-100 million |
Science and Technology Platform
Glutaminyl Cyclase (QC) and pGlu-Aβ
...
Overview
Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for [Alzheimer's disease](/diseases/alzheimers-disease) and other neurodegenerative conditions. Headquartered in Amsterdam, Netherlands, with operations in Munich, Germany, Vivoryon is pioneering a novel approach targeting glutaminyl cyclase (QC) inhibition to prevent the formation of toxic [amyloid-beta](/proteins/amyloid-beta) oligomers[@vivoryon].
The company was founded in 2006 as a spin-off from the University of Munich (LMU), leveraging over a decade of academic research on the role of glutaminyl cyclase in neurodegenerative disease. Vivoryon's lead candidate, varoglutamstat (formerly PQ912), represents one of the few disease-modifying approaches in clinical development that targets a specific toxic amyloid-beta species rather than amyloid plaque formation broadly.
Company Profile
| Attribute | Details |
|-----------|---------|
| Headquarters | Amsterdam, Netherlands (legal) |
| Operations | Munich, Germany |
| Founded | 2006 |
| Stock Exchange | Euronext Amsterdam |
| Ticker | VVY |
| Employees | ~50 |
| Market Cap | ~€50-100 million |
Science and Technology Platform
Glutaminyl Cyclase (QC) and pGlu-Aβ
Vivoryon's therapeutic approach is based on the inhibition of glutaminyl cyclase (QC), an enzyme that catalyzes the N-terminal cyclization of glutamate residues in certain proteins, including [amyloid-beta](/proteins/amyloid-beta). This post-translational modification produces pyroglutamate-modified amyloid-beta (pGlu-Aβ or AβpE3-x), a particularly neurotoxic variant of the amyloid-beta peptide[@schilling2012].
Key characteristics of pGlu-Aβ:
- Enhanced aggregation: pGlu-Aβ forms highly stable, low-molecular-weight oligomers that are more toxic than full-length Aβ1-42[@moreno2019]
- Early presence: pGlu-Aβ species appear early in AD progression and are found in the brains of AD patients at higher levels than in age-matched controls
- Seeding activity: pGlu-Aβ acts as a "seed" that accelerates the aggregation of other Aβ species
- Resistance to degradation: pGlu-Aβ is more resistant to proteolytic clearance than unmodified Aβ
The enzyme glutaminyl cyclase exists in two isoforms:
- QC (glutaminyl cyclase): The secreted form that primarily modifies Aβ
- QPCTL (glutaminyl-peptide cyclotransferase-like): A structurally related enzyme that may have overlapping substrate specificity
Mechanism of Action
Varoglutamstat works by inhibiting the glutaminyl cyclase enzyme, thereby preventing the formation of pGlu-Aβ species. This mechanism is distinct from other approaches in the AD pipeline:
Therapeutic benefits of QC inhibition:
Lead Candidate: Varoglutamstat (PQ912)
Development Timeline
| Year | Milestone |
|------|-----------|
| 2006 | Company founded as LMU spin-off |
| 2015 | Varoglutamstat enters Phase 1 clinical trials |
| 2018 | Phase 2a SAPIR trial initiated |
| 2021 | Phase 2b VIVIAD trial initiated |
| 2024 | Phase 2b ongoing, multiple publications |
Phase 1 Studies
Phase 1 clinical trials demonstrated several important findings[@poirier2020]:
- Dose escalation: Varoglutamstat was well-tolerated at single and multiple ascending doses up to 800mg daily
- Brain penetration: CSF sampling confirmed adequate brain exposure at therapeutic doses
- Target engagement: Dose-dependent inhibition of QC activity in CSF was demonstrated
- Safety profile: No serious adverse events were reported; most adverse events were mild and transient
Phase 2a SAPIR Trial
The SAPIR trial was a randomized, double-blind, placebo-controlled study evaluating varoglutamstat in patients with early Alzheimer's disease. Key findings included:
Efficacy signals:
- Significant reduction in pGlu-Aβ levels in cerebrospinal fluid (CSF)
- Improvement in memory function measures compared to placebo
- Dose-dependent cognitive effects observed
- Good tolerability across all dose groups
- No significant differences in adverse events between treatment and placebo groups
- No dose-limiting toxicities identified
Phase 2b VIVIAD Trial
The ongoing Phase 2b VIVIAD study is evaluating varoglutamstat in a larger patient population with early Alzheimer's disease:
- Design: Randomized, double-blind, placebo-controlled
- Population: Patients with mild cognitive impairment (MCI) due to AD or mild AD dementia
- Primary endpoints: Cognitive measures and biomarkers
- Sites: Multiple centers across Europe
- Status: Enrollment ongoing
Research Programs Beyond Varoglutamstat
| Program | Indication | Stage | Notes |
|---------|------------|-------|-------|
| Varoglutamstat (PQ912) | Early AD | Phase 2b | Lead candidate |
| PQ1565 | Inflammatory disease | Preclinical | QC inhibition |
| PQ1106 | Neurodegeneration | Discovery | Next-generation QC inhibitor |
| QC inhibitor platform | Various | Discovery | Multiple programs |
Competitive Landscape
Varoglutamstat occupies a unique position in the AD therapeutic landscape:
Comparison with Other Approaches
| Approach | Target | Company | Stage | Mechanism |
|----------|--------|---------|-------|-----------|
| Varoglutamstat | pGlu-Aβ | Vivoryon | Phase 2b | QC inhibitor |
| Lecanemab | Aβ plaques | Eisai/Biogen | Approved | Anti-amyloid mAb |
| Donanemab | N3pG Aβ | Eli Lilly | Approved | Anti-amyloid mAb |
| Semaglintide | Aβ aggregation | Eli Lilly | Phase 2 | GLP-1 analog |
| Blarcamesine | Sigma-1 agonist | Anavex | Phase 2/3 | Neuroprotective |
Advantages of QC Inhibition
Challenges and Risks
- Limited efficacy data: Phase 2b results not yet available
- Competition: Approved anti-amyloid antibodies may dominate the market
- Regulatory pathway: Novel mechanism may face additional scrutiny
- Biomarker validation: pGlu-Aβ as a surrogate endpoint not yet validated by regulators
Scientific Background
The Amyloid Cascade Hypothesis and Its Refinement
The amyloid cascade hypothesis, originally proposed by Hardy and Higgins in 1992, posits that accumulation of amyloid-beta peptide in the brain is the primary event in Alzheimer's disease that triggers downstream pathological processes including tau phosphorylation, neuroinflammation, synaptic loss, and neuronal death[@selkoe2001]. While this hypothesis has been foundational to AD research, the approval of lecanemab and donanemab has validated the amyloid-targeting approach while also revealing its limitations.
Modern understanding has refined the hypothesis to focus on soluble oligomeric species rather than insoluble plaques[@haass2007]. Amyloid-beta oligomers are now recognized as the most toxic species, causing synaptic dysfunction and cognitive decline even before substantial plaque deposition occurs[@benilova2010]. This understanding has shifted drug development toward targeting specific toxic Aβ species rather than plaque removal broadly.
Pyroglutamate-Modified Aβ (pGlu-Aβ) in Disease Pathogenesis
pGlu-Aβ represents a particularly aggregation-prone and neurotoxic variant of the amyloid-beta peptide. The N-terminal glutamination catalyzed by glutaminyl cyclase converts Aβ1-40 and Aβ1-42 into pGlu-Aβ3-40/42, which exhibit several pathogenic properties[@schilling2012]:
Aggregation kinetics: pGlu-Aβ3-42 shows accelerated oligomerization compared to unmodified Aβ1-42, forming stable low-molecular-weight oligomers within hours rather than days. These oligomers are resistant to dissociation and serve as templates for further aggregation.
Neurotoxicity: In vitro studies demonstrate that pGlu-Aβ oligomers are more potent inducers of oxidative stress, mitochondrial dysfunction, and synaptic damage than equivalent concentrations of unmodified Aβ. The toxic mechanism involves disruption of calcium homeostasis, activation of apoptotic pathways, and impairment of synaptic plasticity[@moreno2019].
Seeding activity: pGlu-Aβ acts as an efficient "seed" that catalyzes the aggregation of normal Aβ species. This prion-like property means that even small amounts of pGlu-Aβ can accelerate the formation of toxic oligomers throughout the brain[@wanker2014].
Early appearance: Post-mortem studies show elevated pGlu-Aβ in the brains of individuals with mild cognitive impairment and early AD, suggesting these species appear early in disease pathogenesis. The presence of pGlu-Aβ in Down syndrome patients prior to classic AD pathology indicates these modified peptides may be among the earliest markers of amyloid pathology.
Glutaminyl Cyclase as a Therapeutic Target
Glutaminyl cyclase (QC) catalyzes the conversion of N-terminal glutamine to pyroglutamate in various substrates, including amyloid-beta. The enzyme exists in two forms[@sykes2011]:
- Secretory QC (sQC): The predominant form expressed in the brain, localized to secretory vesicles and the extracellular space
- Glutaminyl-peptide cyclotransferase-like (QPCTL): A related enzyme with overlapping substrate specificity
QC expression is elevated in AD brain tissue[@craven2012], particularly in regions vulnerable to amyloid pathology. Studies show QC activity correlates with pGlu-Aβ burden, suggesting QC inhibition represents a logical therapeutic strategy.
Preclinical Development of QC Inhibitors
The development of varoglutamstat (PQ912) followed a systematic drug discovery process[@sykes2011]:
The binding mode of PQ912 to secretory glutaminyl cyclase has been characterized through crystallography and computational modeling[@chandran2021], confirming the compound binds to the active site and stabilizes the enzyme in an inactive conformation.
Combination Therapy Potential
Preclinical studies suggest QC inhibition may synergize with other therapeutic approaches. Combination of varoglutamstat with anti-Aβ monoclonal antibodies shows additive effects on amyloid pathology in transgenic mouse models[@hoffmann2021], providing a rationale for potential combination therapy in clinical development.
Clinical Development Strategy
Target Population
Varoglutamstat is being developed for:
- Early AD: Patients with MCI due to AD or mild AD dementia
- Biomarker-positive: Patients with confirmed amyloid pathology via PET or CSF biomarkers
This population aligns with the growing recognition that early intervention is critical for disease-modifying therapies in AD[@bateman2012][@jack2018]. The window of opportunity for meaningful disease modification likely occurs before substantial neuronal loss has occurred.
Biomarker Strategy
Vivoryon is employing a comprehensive biomarker approach:
- pGlu-Aβ in CSF: Direct measure of target engagement
- Total Aβ and tau: Standard AD biomarkers
- Neurofilament light chain (NfL): Marker of neuronal injury
- Neuroimaging: PET and MRI to assess brain changes
The ability to demonstrate target engagement through CSF pGlu-Aβ reduction represents a significant advantage, as it provides evidence that the drug is hitting its intended molecular target.
Clinical Trial Design Considerations
The VIVIAD trial design reflects lessons learned from previous AD clinical trials[@vijverberg2021]:
- Enriched population: Selection for biomarker-confirmed AD rather than clinical diagnosis alone
- Early disease stage: Focus on MCI and mild dementia where disease modification is most likely
- Dose-finding: Incorporation of multiple dose levels to identify optimal exposure
- Biomarker co-primary endpoints: Integration of cognitive and biomarker measures
Competitive Landscape and Market Analysis
AD Therapeutic Market Overview
The Alzheimer's disease market represents one of the largest unmet needs in pharmaceutical development:
- Over 6 million Americans living with AD (as of 2024)
- Global prevalence expected to exceed 150 million by 2050
- Current therapies provide only symptomatic benefit
- Disease-modifying therapies represent a potential $20+ billion market
Comparison with Approved and Pipeline Therapies
| Approach | Target | Company | Stage | Mechanism |
|----------|--------|--------|-------|-----------|
| Varoglutamstat | pGlu-Aβ | Vivoryon | Phase 2b | QC inhibitor |
| Lecanemab | Aβ plaques | Eisai/Biogen | Approved | Anti-amyloid mAb |
| Donanemab | N3pG Aβ | Eli Lilly | Approved | Anti-amyloid mAb |
| Semaglintide | Aβ aggregation | Eli Lilly | Phase 2 | GLP-1 analog |
| Blarcamesine | Sigma-1 agonist | Anavex | Phase 2/3 | Neuroprotective |
Strategic Positioning
Varoglutamstat's oral delivery and novel mechanism position it differently from approved monoclonal antibody therapies:
Corporate Information
History and Milestones
Vivoryon was founded in 2006 as a spin-off from the University of Munich (LMU). The company initially focused on developing QC inhibitors for various indications. In 2017, Vivoryon merged with the German company Vivoryon Therapeutics AG to strengthen its pipeline. The company went public on the Euronext Amsterdam stock exchange in 2019.
In 2024, Vivoryon completed an acquisition to consolidate its position and focus resources on the varoglutamstat program.
Financial Information
- Stock Exchange: Euronext Amsterdam
- Ticker: VVY
- IPO: 2019
- Market Cap: Approximately €100-200 million (as of 2024)
- Cash runway: Through Phase 2b readouts (estimated)
Key Partnerships
Vivoryon has collaborated with:
- Academic institutions (University of Munich, other European universities)
- Pharmaceutical companies for potential commercialization partnerships
- Clinical trial networks across Europe
Clinical Development Strategy
Target Population
Varoglutamstat is being developed for:
- Early AD: Patients with MCI due to AD or mild AD dementia
- Biomarker-positive: Patients with confirmed amyloid pathology via PET or CSF biomarkers
This population aligns with the growing recognition that early intervention is critical for disease-modifying therapies in AD.
Biomarker Strategy
Vivoryon is employing a comprehensive biomarker approach:
- pGlu-Aβ in CSF: Direct measure of target engagement
- Total Aβ and tau: Standard AD biomarkers
- Neurofilament light chain (NfL): Marker of neuronal injury
- Neuroimaging: PET and MRI to assess brain changes
Future Outlook
Potential Milestones (2025-2026)
- Phase 2b VIVIAD trial interim analysis
- Phase 2b VIVIAD trial completion
- Regulatory interactions for Phase 3 design
- Partnership or acquisition discussions
- Potential Phase 3 initiation
Market Opportunity
The Alzheimer's disease market represents one of the largest unmet needs in pharmaceutical development:
- Over 6 million Americans living with AD (as of 2024)
- Global prevalence expected to exceed 150 million by 2050
- Current therapies provide only symptomatic benefit
- Disease-modifying therapies represent a potential $20+ billion market
External Links
- [Vivoryon Website](https://www.vivoryon.com/)
- [ClinicalTrials.gov - Varoglutamstat](https://clinicaltrials.gov)
- [PubMed Search: Varoglutamstat](https://pubmed.ncbi.nlm.nih.gov/?term=varoglutamstat+Alzheimer)
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | companies-vivoryon |
| kg_node_id | None |
| entity_type | company |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-427a2342b4b0 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'companies-vivoryon'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-companies-vivoryon?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Vivoryon Therapeutics](http://scidex.ai/artifact/wiki-companies-vivoryon)
http://scidex.ai/artifact/wiki-companies-vivoryon